Rational design of inhibitors that bind to inactive kinase conformations
Top Cited Papers
- 16 June 2006
- journal article
- perspective
- Published by Springer Nature in Nature Chemical Biology
- Vol. 2 (7) , 358-364
- https://doi.org/10.1038/nchembio799
Abstract
The majority of kinase inhibitors that have been developed so far—known as type I inhibitors—target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated. Recently, crystal structures of inhibitors such as imatinib (STI571), BIRB796 and sorafenib (BAY43-9006)—known as type II inhibitors—have revealed a new binding mode that exploits an additional binding site immediately adjacent to the region occupied by ATP. This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation. Here, we present a structural analysis of binding modes of known human type II inhibitors and demonstrate that they conform to a pharmacophore model that is currently being used to design a new generation of kinase inhibitors.Keywords
This publication has 27 references indexed in Scilit:
- SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitorsPublished by Elsevier ,2005
- Exploiting structural principles to design cyclin-dependent kinase inhibitorsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2005
- Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead GenerationJournal of Medicinal Chemistry, 2004
- Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinaseBioorganic & Medicinal Chemistry Letters, 2004
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFPublished by Elsevier ,2004
- Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesisBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2004
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Protein kinases — the major drug targets of the twenty-first century?Nature Reviews Drug Discovery, 2002
- Inhibition of p38 MAP kinase by utilizing a novel allosteric binding siteNature Structural & Molecular Biology, 2002
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000